... SAN DIEGO Aug. 28 /- Amylin Pharmaceutical...The live presentations will be Web cast and recordings will be madea...About Amylin Pharmaceuticals ...Amylin Pharmaceuticals is a biopharmaceutical company committed toimp...

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be presenting at the Thomas Weisel Healthcare
Conference in Boston on Wednesday, September 3, 2008 at 9:10 a.m. ET, at
the BioCentury NewsMakers Conference in New York on Thursday, September 4,
2008 at 11:30 a.m. ET, and at the Morgan Stanley Global Healthcare
Unplugged Conference in New York on Tuesday, September 9, 2008 at 10:55
a.m. ET. Mark G. Foletta, Amylin's Senior Vice President of Finance and
Chief Financial Officer, will be providing corporate overviews at Thomas
Weisel and BioCentury. Daniel M. Bradbury, Amylin's President and Chief
Executive Officer, will be providing a corporate overview at Morgan
Stanley.

The live presentations will be Web cast, and recordings will be made
available following the event. The Web casts and recordings will be
accessible through Amylin's corporate Web site, located at
http://www.amylin.com. To access the live Web casts, please log on to
Amylin's site approximately fifteen minutes prior to the presentations to
register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
headquartered in San Diego, California with over 2,000 employees
nationwide. Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.